Sec Form 4 Filing - KAY CHRISTINA @ INTEGRATED BIOPHARMA INC - 2023-05-25

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person KAY CHRISTINA 2. Issuer Name and Ticker or Trading Symbol INTEGRATED BIOPHARMA INC [ INBP] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner X __ Officer (give title below) _____ Other (specify below) Co-Chief Executive Officer (Last) (First) (Middle) C/O 225 LONG AVENUE 3. Date of Earliest Transaction (MM/DD/YY) 05/25/2023 (Street) HILLSIDE, NJ07205 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 05/25/2023( 1 ) 05/25/2023 A 3,410,512 A $ 0.4 ( 2 ) 3,410,512 I As Co-Executor of the Estate of E Gerald Kay Common Stock 09/20/2023 09/20/2023 A( 3 ) 50,000 A $ 0.09 1,273,467 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 0.23 05/25/2023( 1 ) 05/25/2023( 1 ) A 150,000 05/24/2019( 4 ) 03/20/2024 Common Stock 150,000 $ 0 150,000 I As Co-Executor of the Estate of E Gerald Kay Stock Option (right to buy) $ 0.72 05/25/2023( 1 ) 05/25/2023( 1 ) A 66,667 11/04/2021( 5 ) 03/20/2024 Common Stock 66,667 $ 0 66,667 I As Co-Executor of the Estate of E Gerald Kay Stock Option (right to buy) $ 1.045 05/25/2023( 1 ) 05/25/2023( 1 ) A 21,667 11/03/2022 03/20/2024 Common Stock 21,667 $ 0 21,667 I As Co-Executor of the Estate of E Gerald Kay Stock Option (right to buy) $ 0.09 09/20/2023 09/20/2023 D 50,000 06/02/2015 06/02/2025 Common Stock 50,000 $ 0 200,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other KAY CHRISTINA C/O 225 LONG AVENUE HILLSIDE, NJ07205 X X Co-Chief Executive Officer Signatures /s/ Christina Kay 09/21/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Date Ms. Kay was appointed Co-Executor of the Estate of E Gerald Kay. ( 2 )Closing price of the Issuer's Common Stock on March 20, 2023, date of transfer into the Estate of E Gerald Kay. ( 3 )50,000 common stock shares acquired upon exercise of stock option grant dated June 2, 2015. ( 4 )25,000 vested on May 24, 2019 and in 41,667 vested each May 24, 2020 and 2021 and 41,666 vested on May 24, 2022. ( 5 )33,334 vested on November 4, 2021, the one year anniversary of the grant date and 33,333 vested on November 4, 2022, the second year anniversary of the grant date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.